. An increase of the mutation rate caused by exposure to a genotoxic agent will, in multiplicative 5 Present address: China Institute for Radiation Protection, Taiyuan, interaction with inherited or acquired factors promoting growth Shanxi 030006, China and clonal expansion, lead to an increased probability (risk) Cancer risk assessment of polycyclic aromatic hydrocarof cancer. At low doses this may be described by a linear bons (PAH) is complicated by several of these compounds multiplicative model in which the risk increment is proportional exerting a promoter action leading to high tumour incidto the background incidence multiplied by the dose of the ences at high doses. Cancer risks at low doses corresponding genotoxic agent or metabolite (Granath et al., 1999) . to the uptake from air and food in the general environment A cancer risk estimation by extrapolation of incidence or would best be estimated on the basis of measurement of mortality data from animal experiments is rendered inin vivo target doses of genotoxic (mutagenic) intermediates appropriate because of the promoter action of many PAH and a determination of mutation frequency per unit of leading to convex dose-response curves with very high tumour dose. In experiments ultimately aiming at a risk assessment incidences at high experimental doses. This promoter action, of environmental PAH from in vivo doses benzo[a]pyrene i.e. an increment of propensity for proliferation, is probably (BaP) was chosen as a model. γ-Radiation has earlier been due to interaction of the unmetabolized hydrocarbons with the used as a reference standard in cancer risk estimation of Ah receptor (Sjögren et al., 1996; Enan et al., 1998) . At the genotoxic chemicals where dose equivalents (rad-equivaoften low exposure levels in the general environment the lents) have been shown to give reliable risk estimates cancer risk increments due to PAH will be mainly determined for several alkylating agents. Variation in dose of BaP by the induced incremental mutation frequencies rather than diolepoxide between organs was studied by measurement this promoter action. These mutation frequencies should be of deoxyguanosine-N 2 adducts in DNA after administration assumed to follow linear dependencies on doses of genotoxic metabolites, in many cases diolepoxides, of the PAH. For the of BaP by gavage to mice of a strain with reduced DNA achievement of a reliable risk estimation of a genotoxic factor repair (Xpa -/-). The adduct levels in spleen, forestomach, it is necessary to know the target doses of the genotoxic stomach and small intestine were approximately the same; factor and the relationship between induced mutation frequency with the adduct level in spleen as reference it was twice as and target dose. high in liver and lung and about half as high in colon
In the present study, benzo[a]pyrene (BaP) was used as a tissue. A chemical or radiation dose is proportional to the model and indicator of PAH. A benzo[a]pyrene diol epoxide cumulative frequency of putatively premutagenic changes (BPDE) was assumed to be the major mutagenic metabolite (premutagenic hits) in DNA. The mutation frequency per through reaction with deoxyguanosine-N 2 (dGuo-N 2 ) in DNA premutagenic hit (genotoxic chemicals) and per unit of and the formation of dGuo-N 2 -BPDE adducts being considered dose (γ-radiation) were calculated from acutely exposed as putatively premutagenic events ('premutagenic hits'). The V79 cells in order to determine the mutagenic effectiveness level of this adduct per unit amount of DNA could be used as of each agent. Based on the mutagenic effectiveness detera measure of dose, provided losses due to repair etc. could be mined in this study 10 -4 Gy can be regarded equally avoided. To minimize such losses the inter-organ distribution effective in causing phenotypically expressed HPRT of dose was studied in mice deficient in excision repair, mutations as the dose of BaP which causes the formation and the relationship between frequencies of HPRT mutation of one deoxyguanosine-N 2 adduct per cell.
and premutagenic hits were studied in V79 cells following acute exposure of short duration, where it could be assumed that the measured levels of dGuo-N 2 -DNA adducts reflect the cumulative levels of premutagenic events. With respect Introduction to mutants per premutagenic hit BaP was compared with The present study concerns pieces of knowledge required in γ-radiation and, using literature data, other PAH and simple the development of reliable methods for cancer risk estimation alkylators. of polycyclic aromatic hydrocarbons (PAH). These compounds are general pollutants in air and food (Beckman Sundh et al., Materials and methods 1998; World Health Organization, 1998, and also occur in Animals and treatment certain occupational environments (World Health Organization, An Xpa deficient and p53 heterozygous transgenic mouse strain with a C57Bl/6 genetic background crossbred as described previously (van Oostrom et al., 1998) . Preliminary estimates indicate that PAH in urban air 6 To whom correspondence should be addressed. Email: margareta.tornqvist@mk.su.se 1999) was used in the experiment. From the age of 17 weeks the mice (two males and three females) were treated by gavage with 13 mg BaP (Fluka, Dogra et al. (1990) . Colon 2.0 Ϯ 0.1 26 Ϯ 9 a Treatments of cells a Average from two mice (male and female). Cells were reseeded in DMEM using either (A) 2ϫ10 6 cells per 75 cm 2 b Average from five mice (two males and three females). culture flask or (B) 1ϫ10 6 cells per 25 cm 2 culture flask. After one day of growth the medium was changed to 20 ml/flask of Hank's balanced salt solution (HBSS) containing Ca 2ϩ and Mg 2ϩ (supplemented with HEPES, antibiotics and calf serum, see above). intestine; with the adduct level in spleen as reference it was Acute intracellular exposure of the XEM2 cells to Ϯ(anti)r-7,t-8-dihydroxyabout twice as high in liver and lung (115 and 146) and about t-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene (BPDE) was obtained by treatment with Ϯ trans -7,8-dihydroxy-7,8-dihydrobenzo[a] pyrene (BPD) half as high in colon tissue (26). (Table II) . Survival decreased with dose to 33% at the highest out in groups of three flasks per BPD concentration; three flasks were used as controls (addition of 140 µl DMSO). After addition of BPD and DMSO dose. The cloning efficiency (CE) was 100-78% in the dose the media were thoroughly mixed and kept in the CO 2 incubator for 3 h. range 0-700 nM BPD. BPD treatment with 50-700 nM gave
The cells from group B were exposed to 137 Cs γ-radiation doses in the adduct levels in the range 60-300ϫ10 3 adducts per cell. (Table III) 
. Survival decreased in approximately linear
Mouse tissues (0.1-0.2 g) were cut into small pieces and then homogenized.
dependence on dose to 27% at the highest dose. Cloning A major part of the BPD-treated, HBSS washed and trypsinized XEM2 cells efficiency (CE) was 100-77% in the dose interval 0-5 Gy.
(8-12ϫ10 6 ) were spun down at 3000 g. The pellets from homogenized mouse tissue and XEM2 cells were washed in 10 ml buffer (0.15 M NaCl, 10 mM Tris-HCl pH 7.4) and retrieved after centrifugation at 2000 r.p.m. for 10 min.
Discussion
The isolation and digestion of DNA were then done according to Yang et al. (1996) . 32 P post-labelling Cancer risk estimation of radiation or reactive chemicals has
Doses, premutagenic hits and mutants per premutagenic hit
The DNA concentration was determined by measurement of absorbance at to be based on assessed in vivo doses (particularly target doses, 260 nm and DNA purity by the A 260 /A 280 ratio according to Szyfter et al. (1994) . The 32 P post-labelling was done according to Yang et al. (1996) . All i.e. doses at tumour sites). Doses of chemically reactive the adduct spots were excised together for Cerenkov counting while keeping compounds/metabolites are defined as the integrals over time the excised areas from different plates separate. The radioactivity measured of concentration (e.g. in mMh), which is comparable with at the adduct spot area in the negative control plate was used as background radiation doses expressed as energy absorbed per unit of mass value when the adduct levels were calculated. In all experiments positive (Gy ϭ Jϫkg -1 ) (Ehrenberg et al., 1983) . It should be stressed BPDE-dGMP and BPDE-treated DNA standards, see Phillips and Castegnaro (1999) , and negative standards (digestion solution without DNA) were used. that effects of inherited or acquired factors that modify the The recovery of the BPDE-treated DNA (1.11 adducts/10 8 nucleotides) was dose, i.e. changes in rates of formation or disappearance used to adjust the adduct levels in the in vitro samples. The average recovery of reactive intermediates of chemicals, are included in the from four analyses was 35% and in compatibility with earlier quantitative measured dose. 32 P-post-labelling studies (Segerbäck and Vodicka, 1993) . The measured amounts of adducts were divided by 0.35 to obtain total adduct level. In order
The frequencies of primary putatively premutagenic changes to express adduct levels per cell the calculated levels of adducts per nucleotide ('premutagenic hits') formed in DNA are proportional to were multiplied by 12ϫ10 9 nucleotides per mammalian cell (Lehninger, 1975) . the measured dose. An observed frequency of mutants per premutagenic hit, in the genome or the coding sequence of a Results gene, reflects the probability that a primary lesion leads to mutation after repair, apoptosis and other processes that modify Levels of observed BPDE adducts to dGuo-N 2 of DNA in different tissues from Xpa deficient mice are given in Table I. the manifestation of a mutation after the event considered as the premutagenic hit. The data were collected from control mice and mice treated with BaP per os (total dose in 7 weeks 273 mg/kg). The
The present paper deals with the distribution of dose over target organs, the frequency of premutagenic hits in DNA per adduct levels were in the range 55-63 dGuo-N 2 adducts/ 10 8 nucleotides in spleen, forestomach, stomach and small unit of dose, as well as the probability that a premutagenic hit For computation of dose (e.g. in mMh) the rate constant, 
Target dose and variation between tissues
BaP fed to rats is to a large extent excreted in faeces directly 0 100 100 6.4 Ϯ 1.4 -or after entero-hepatic circulation (Stavric and Klassen, 1994 (Penning et al., 1999) . However, the diol epoxides of BaP exhibit the strongest genotoxic action observed among known leads to mutation, i.e. in principle, data of importance in cancer BaP metabolites. This is in acceptable agreement with data risk estimation of a genotoxic agent.
for several other diol epoxides of PAH (World Health Organiza-DNA adducts as a measure of dose tion, 1998).
In the present study the adduct levels were measured in In the present study, doses, D, of the reactive diolepoxide of seven different tissues in order to learn more about the BaP (BPDE) were assessed from the levels of its adducts to distribution of BaP and its metabolites after chronic exposure. dGuo-N 2 in DNA. Since a dose, defined as the integral over
The found adduct levels were highest in liver and lung. The time of concentration, is proportional to the cumulative level levels in spleen, forestomach, stomach and small intestine of adducts formed and since relevant data for the kinetics of being 2-3-fold lower (Table I ). The higher adduct levels in the decrease of the adduct level through repair (and other liver and, possibly, lung may reflect contributions from induced processes) were not available, the experimental conditions CYP1A activities, single doses of 13 mg/kg BaP being slightly were chosen with the aim that measured DNA adduct levels above the threshold for induction of ethoxyresorufin deethylase should approach the cumulative levels of adducts formed.
(EROD) activity in liver of C57Bl/6 mice (Vaca et al., 1992) . Thus, an acute exposure of V79 cells was gained by treatment Relatively high systemic adduct levels in the lung after oral with BPD (the 7,8-trans-dihydrodiol of BaP) for 3 h using a treatment have also earlier been observed in an Xpa -/-mouse cell line, XEM2, expressing CYP1A1, and preparing DNA for strain (de Vries et al., 1997) and in a study with rats (Godschalk adduct analysis directly after treatment. From available data et al., 2000) . In the present study the adduct level in the colon (MacLeod et al., 1991; Chen et al., 1992; Celotti et al., 1993) was exceptionally low, probably due to a fast decrease of the it was estimated that a loss of adducts through repair could be DNA adduct level through high cell division rate in this tissue. 20% at most under these conditions.
The observed adduct level in the forestomach does not disclose In the study of dose distribution in vivo a mouse strain an enhanced rate of bioactivation of BaP, expected for this deficient in excision repair (Xpa -/-) was used. In a previous tissue, which in administration by gavage or via the feed may experiment with Xpa -/-mice under the same conditions be seen as the site of application. The high incidence of (de Vries et al., 1997) it was shown that adduct levels in tumours in the forestomach which predominates relative to studied organs increased linearly with time of BaP treatment other tumours (Chen and Chu, 1991; Culp et al., 1998) might for up to 9 weeks. It may therefore be assumed that, unless therefore be provoked mainly by a promoter action of the fast cell division occurs, the adduct levels after 7 weeks unmetabolized hydrocarbon. The cancer-risk/dose relationship exposure in the present study will be representative of the in this organ calls for further experimental elucidation. cumulative levels of the adducts formed and thus of the doses.
Putatively premutagenic adducts formed by PAH In the previously mentioned study (de Vries et al., 1997 ) the adduct levels were 2-3-fold lower in repair proficient mice
The in vitro study was focused on DNA damages caused by metabolites from BPD, where formation of BPDE is favoured. (Xpa ϩ/ϩ ) .
The adducts formed in DNA by diol epoxides of PAH are regions of the HPRT gene. This similarity may very well be fortuitous but is to some extent expected, at least for low mainly adducts bound to the exocyclic amino groups dGuo-N 2 and deoxyadenosine-N 6 (dAdo-N 6 ) (Szeliga and Dipple, molecular mass alkylators, which exhibit a predictability of mutagenic potency from rates of reactions towards DNA 1998) and are regarded as putatively premutagenic events of major importance. Studies on cells treated with PAH DE oxygens (Vogel et al., 1996) . As for ionizing radiation, too little is known about primary in vitro have given relevant information about the genotoxic action of such adducts and the adduct patterns are well effects to permit a proper definition of premutagenic hits. If we generously define premutagenic hits as primary ionizations correlated with mutational spectra. The manifest structural changes seen in DNA after PAH DE exposure are mainly in hydrated DNA or as the sum of measurable structural changes (single-and double-strand breaks and base damages point mutations (only 1-3% are deletions and insertions) (Bigger et al., 2000) . After exposure to bay region PAH DE according to Ward (1994) , the number of HPRT mutants per premutagenic hit in the genome turns out to be about 5-(such as BPDE), which give a comparatively high proportion of dGuo-N 2 adducts, substitutions at GC base pairs (especially fold higher than the corresponding values for the chemicals discussed. This is due to the occurrence of genotoxically GC→TA transversions) are seen (Lambert et al., 1994; Wei et al., 1994; Szeliga and Dipple, 1998; Bigger et al., 2000) .
effective clusters of primary events (Goodhead, 1994) . The genetic effects comprise various kinds of chromosomal After exposure to fjord region PAH DE (e.g. benzo[c]phenanthrene), which give mixtures of dGuo-N 2 and Ado-N 6 rearrangements including deletions of single or several loci and was recognized early by Lea (1946) to be due to ionization adducts, substitutions at GC and AT base pairs are seen (Szeliga and Dipple, 1998; Bigger et al., 2000) .
clusters produced by δ-rays and track-ends of ionizing particles.
Viewpoints on cancer risk estimation Mutants per putatively premutagenic hit
From the HPRT mutation frequencies (mutants per cell) and From the comparison of BPDE and γ-radiation with respect to HPRT mutant frequencies in V79 cells (Tables II and III ) dGuo-N 2 adduct levels (adducts per cell) in the BPD treated XEM2 cells observed in the present experiment, the mutants it follows that one dGuo-N 2 BPDE adduct per cell is associated with about 4ϫ10 -9 mutants per cell and that 1 Gy γ-radiation per premutagenic hit in the genome (MPH) were calculated (Table II) . The average value was 4.4 Ϯ 1.4 (SD)ϫ10 -9 induces 3-6ϫ10 -5 mutants per cell, i.e. that a BPDE dose leading to the formation of one adduct per cell has approximutants per adduct. For alkylating agents giving rise mainly to point mutations, MPH may be referred to as the calculated mately the same mutagenic effectiveness as 10 -4 Gy. In view of the demonstration that the ratio of the in vitro mutagenic number of premutagenic hits in the coding regions (provided that premutagenic hits occur at random in the genome). The potencies of ethylene oxide and γ-radiation is approximately the same as the ratio of carcinogenic potencies of these agents sum of the coding regions (exons) is 654 bp in HPRT (Jansen et al., 1992) out of the 6ϫ10 9 bp in the genome. MPH for the (Granath et al., 1999) it is probable that the found ratio for BaP and γ-radiation is valid for their relative carcinogenic coding regions of the gene would thus (from data in Table II) be computed to 0.04 for BPD, following acute exposure with potencies as well.
To the extent that the mouse model is relevant to man the preparation and analysis of dGuo-N 2 adducts directly after treatment, the fraction lost by repair being negligable (cf. data indicate that, following intake via the gastro-intestinal tract, i.e. the predominant route for human uptake of PAH above).
From earlier studies in V79 cells (HPRT mutants and dGuo- (Hemminki and Pershagen, 1994; Törnqvist and Ehrenberg, 1994; Beckman Sundh et al., 1998) (Phillips et al., 1991) values in the range of 0.01-0.04 per premutagenic hit in the HPRT exons within such a relatively narrow range is advantageous with regard to estimation of cancer risk at low doses of PAH. were calculated; these values are consistent with the present values for V79 cells treated by BPD.
Since extrapolation from animal cancer tests would exaggerate the risk due to promoter action at higher doses, the An in vivo value for MPH could be obtained from data (de Vries et al., 1997; Boerrigter, 1999; Swiger et al., 1999) for radiation-dose equivalents of chemical doses appears at present to be a practicable way to estimate the risk coefficient in BaP-induced frequencies of phenotypically expressed mutation per lacZ gene (3000 bp) and DNA adduct levels in transgenic combination with a multiplicative model (Granath et al., 1999) . For example, a dose of BaP leading to an incremental adduct C57Bl/6 mice (Xpa deficient and proficient). MPH are in the range 0.01-0.02 (Xpa -/-) and 0.01-0.05 (Xpa ϩ/ϩ ) in liver, lung level of 1ϫ10 -8 dGuo-N 2 BPDE adducts per nucleotide would, according to the above comparison of mutagenic potencies, and spleen, i.e. a range overlapping with the one found for HPRT mutations in vitro.
correspond to the risk increment caused by about 1 cGy. However, when it comes to the risk estimation of an For a few simple alkylating agents where dGuo-O 6 alkylations may be considered putatively premutagenic hits exposure situation in humans or for extrapolation from animal experiments, DNA adducts as a measure of dose is rendered similar MPH values were obtained. Ethylene oxide gives 0.03, computed from rad-equivalence determination (Granath et al., questionable because of the modification of initially established adduct levels at varying rates, particularly by repair. For this 1999) and ethylating agents 0.08 computed from data derived from van Zeeland (1988) .
reason the measurement of adducts to blood proteins with well-characterized turnover kinetics has been preferred as a There is thus a conspicuous similarity of mutagens with respect to the probability that a premutagenic hit leads to safer dose monitor, and methods for analysis of PAH adducts to proteins from mutagenic PAH metabolites are being developed manifest mutation. For point mutations this probability is in the order of a few percent for premutagenic hits in the coding (Helleberg and Törnqvist, 2000) .
